• Raymond W. Cohen has worked as an executive in the life sciences industry for over three decades and is an accredited public company director. Cohen currently serves as the CEO of Axonics Modulation Technologies, Inc., (NADSAQ: AXNX) a manufacturer of implantable Sacral Neuromodulation devices for the treatment of bladder and bowel disorders. In Q1 2020, following U.S. FDA PMA approval, Axonics achieved the second highest revenue total in the history of the medical device industry for a company’s first full quarter following FDA approval. In October 2020, Cohen was named as Entrepreneur of the Year by Ernst & Young for the Southwest United States. He also currently serves as Chairman of BioLife Solutions Inc. (NASDAQ: BLFS) and as an independent director of privately held BioVentrix, Inc.
  • From 2013 to 2019, Cohen served on the board of Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI), Zurich-based LifeWatch (LIFE.SW) sold to Biotelemetry (NASDAQ: BEAT) and privately held Syncroness, Inc. sold to ALTEN Group, a French multi-billion-dollar engineering services company. From 2010 to 2012, Mr. Cohen served as the CEO of Andera Partners portfolio company Vessix Vascular, Inc., which was acquired by Boston Scientific Corp. Previously, Cohen served as CEO of NASDAQ-listed, Cardiac Science, Inc., a manufacturer of automatic external defibrillators ranked by Deloitte as the 4th fastest growing company in North America in 2004. In his career, Mr. Cohen has been directly responsible for raising over $1 billion in capital from public and venture capital investors. Mr. Cohen holds a B.S. in Business Management from Binghamton University in NY.

1 billion dollars and more in capital raised